MDxHealth Reports 20% Increase in Q2 Revenue, Achieves Positive Adjusted EBITDA of $1.4 Million, and Reduces Net Loss by 36%

Reuters

08/06

MDxHealth Reports 20% Increase in <a href="https://laohu8.com/S/QTWO">Q2</a> Revenue, Achieves Positive Adjusted EBITDA of $1.4 Million, and Reduces Net Loss by 36%

MDxHealth SA has reported its preliminary financial results for the second quarter of 2025, showing a year-over-year revenue increase of 20%, reaching $26.6 million. The company achieved an adjusted EBITDA profitability of $1.4 million for the quarter. This marks the 17th consecutive quarter of 20% or greater revenue growth for MDxHealth, driven by strong demand for its GPS and Confirm mdx tissue-based tests. The company also announced a definitive agreement to acquire the ExoDx business from Bio-Techne Corporation for $15 million in cash and stock over five years. This acquisition is expected to accelerate revenue growth and be accretive to adjusted EBITDA. The net loss for the quarter was reported at $7.372 million, a 36% improvement from the previous year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MDxHealth SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001121542-en) on August 05, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2557419319"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557419319\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557419319?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-06 04:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557419319","market":"us","top_or_hot":-1,"title":"MDxHealth Reports 20% Increase in Q2 Revenue, Achieves Positive Adjusted EBITDA of $1.4 Million, and Reduces Net Loss by 36%","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MDxHealth Reports 20% Increase in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> Revenue, Achieves Positive Adjusted EBITDA of $1.4 Million, and Reduces Net Loss by 36%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        MDxHealth SA has reported its preliminary financial results for the second quarter of 2025, showing a year-over-year revenue increase of 20%, reaching $26.6 million. The company achieved an adjusted EBITDA profitability of $1.4 million for the quarter. This marks the 17th consecutive quarter of 20% or greater revenue growth for MDxHealth, driven by strong demand for its GPS and Confirm mdx tissue-based tests. The company also announced a definitive agreement to acquire the ExoDx business from Bio-<a href=\"https://laohu8.com/S/TECH\">Techne Corporation</a> for $15 million in cash and stock over five years. This acquisition is expected to accelerate revenue growth and be accretive to adjusted EBITDA. The net loss for the quarter was reported at $7.372 million, a 36% improvement from the previous year.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MDxHealth SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001121542-en) on August 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MDxHealth Reports 20% Increase in Q2 Revenue, Achieves Positive Adjusted EBITDA of $1.4 Million, and Reduces Net Loss by 36%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMDxHealth Reports 20% Increase in Q2 Revenue, Achieves Positive Adjusted EBITDA of $1.4 Million, and Reduces Net Loss by 36%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-06 04:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MDxHealth Reports 20% Increase in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> Revenue, Achieves Positive Adjusted EBITDA of $1.4 Million, and Reduces Net Loss by 36%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        MDxHealth SA has reported its preliminary financial results for the second quarter of 2025, showing a year-over-year revenue increase of 20%, reaching $26.6 million. The company achieved an adjusted EBITDA profitability of $1.4 million for the quarter. This marks the 17th consecutive quarter of 20% or greater revenue growth for MDxHealth, driven by strong demand for its GPS and Confirm mdx tissue-based tests. The company also announced a definitive agreement to acquire the ExoDx business from Bio-<a href=\"https://laohu8.com/S/TECH\">Techne Corporation</a> for $15 million in cash and stock over five years. This acquisition is expected to accelerate revenue growth and be accretive to adjusted EBITDA. The net loss for the quarter was reported at $7.372 million, a 36% improvement from the previous year.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MDxHealth SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001121542-en) on August 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MDXH","symbol_name":"MDxHealth, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250805:nNDL1XphZ8:1","article_id":"2557419319","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557419319","pubTimestamp":1754424086,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"MDxHealth SA has reported its preliminary financial results for the second quarter of 2025, showing a year-over-year revenue increase of 20%, reaching $26.6 million. The company achieved an adjusted EBITDA profitability of $1.4 million for the quarter. This marks the 17th consecutive quarter of 20% or greater revenue growth for MDxHealth, driven by strong demand for its GPS and Confirm mdx tissue-based tests. The company also announced a definitive agreement to acquire the ExoDx business from Bio-Techne Corporation for $15 million in cash and stock over five years. This acquisition is expected to accelerate revenue growth and be accretive to adjusted EBITDA. The net loss for the quarter was reported at $7.372 million, a 36% improvement from the previous year.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only a","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"MDXH":"MDxHealth, Inc.","TECH":"Techne Corporation","NDAQ":"纳斯达克OMX交易所"},"translate_title":"MDxHealth报告第二季度收入增长20%，调整后EBITDA为正140万美元，净亏损减少36%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDXH":0.9,"NDAQ":0.9,"TECH":0.9},"content_text":"MDxHealth Reports 20% Increase in Q2 Revenue, Achieves Positive Adjusted EBITDA of $1.4 Million, and Reduces Net Loss by 36%\n    \n\n        MDxHealth SA has reported its preliminary financial results for the second quarter of 2025, showing a year-over-year revenue increase of 20%, reaching $26.6 million. The company achieved an adjusted EBITDA profitability of $1.4 million for the quarter. This marks the 17th consecutive quarter of 20% or greater revenue growth for MDxHealth, driven by strong demand for its GPS and Confirm mdx tissue-based tests. The company also announced a definitive agreement to acquire the ExoDx business from Bio-Techne Corporation for $15 million in cash and stock over five years. This acquisition is expected to accelerate revenue growth and be accretive to adjusted EBITDA. The net loss for the quarter was reported at $7.372 million, a 36% improvement from the previous year.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MDxHealth SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001121542-en) on August 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}